/image%2F3334645%2F20201111%2Fob_fd07bb_sans-titre-1.jpg)
/image%2F3334645%2F20260818%2Fob_b8e1ac_bb45531d-59b7-4251-bb51-1f55d3859604.jpg "Filaggrin: Molecular Biology, Skin Barrier Function, and Disease Associations")
/image%2F3334645%2F20260817%2Fob_a20935_oig2-lllktrmxkpkaiwq.VEsp%3Fw%3D1024%26h%3D1024%26qlt%3D70%26p%3D0%26r%3D0%26o%3D4%26pid%3DImgGn "Filaggrin as a Central Node of Skin Barrier Regulation: Genetic, Epigenetic, Immune, and Microbial Pathways")
/image%2F3334645%2F20260817%2Fob_769ce0_776291438-1121165570477045-80189309492.net%26_nc_cat%3D105%26_nc_ohc%3DkY8rXWOkOe0Q7kNvwFwns0T%26sdl%3D0%26ccb%3D14-4%26oh%3D00_AQFGwqBf_pS4-1Ex0n2Cn6LlX-1-ycvi36ZXvjGGKFtQxQ%26oe%3D6A890DAE%26_nc_sid%3Da21977 "Filaggrin Loss-of-Function and Atopic Dermatitis: Integrating Genetic Susceptibility with Inflammatory Modulation")
/image%2F3334645%2F20260817%2Fob_6e03bc_778902446-1660420015761402-74377930774.net%26_nc_cat%3D106%26_nc_ohc%3DjPLTiUMfQAIQ7kNvwHmu9Ea%26sdl%3D0%26ccb%3D14-4%26oh%3D00_AQGDS7jcCUPi6qHQPXncBjcGRpHGDPPDKiFkQBx7pncfVQ%26oe%3D6A880600%26_nc_sid%3Da21977 "Arctiin and Arctigenin in Cancer Research: Molecular Mechanisms and Limitations")
/image%2F3334645%2F20260816%2Fob_355ea8_771909442-1083901564327417-53339557474.net%26_nc_cat%3D101%26_nc_ohc%3DpBfvuvDEg04Q7kNvwGrfVwK%26sdl%3D0%26ccb%3D14-4%26oh%3D00_AQHGzN5jbFf4i2npaLAuNleEXNUubAP0NsQFwHerDR76tA%26oe%3D6A87EF7A%26_nc_sid%3Da21977 "Burdock Root in Traditional Chinese Medicine: Uses and Properties")
/image%2F3334645%2F20260816%2Fob_6c729e_00fa350b-0dd8-434c-8a0f-3bf954720fea.jpg "Evidence-Based Benefits of Burdock Root: Antioxidants, Fiber & Beyond")
/image%2F3334645%2F20260815%2Fob_bc620d_776497617-2038408443455296-23321386311.jpg "What Makes Witch Hazel Effective? Science, Mechanisms, and Clinical Evidence")
/image%2F3334645%2F20260815%2Fob_0b61ff_1648b369-8789-4bda-ba8e-e0f14509b143.jpg "Witch Hazel and Its Health Benefits: What the Research Shows")
/image%2F3334645%2F20260813%2Fob_b43f9c_769309559-2140073886540951-57767507467.net%26_nc_cat%3D103%26_nc_ohc%3D4QRjV1Bt6mMQ7kNvwEXX8Hm%26sdl%3D0%26ccb%3D14-4%26oh%3D00_AQEewd55H0n7-7rqoPxlPHipVunD0UlbK_kX7bWw4GptTQ%26oe%3D6A840C87%26_nc_sid%3Da21977 "Theoretical Foundations of Cold Laser Water Imprinting")
/image%2F3334645%2F20260813%2Fob_c7a592_bdff188c-2305-4a08-bbd1-19ddd0b42cfe.jpg "Cold Laser-Based Water Imprinting: A Review of Exposure Duration and Proposed Mechanisms")
Low-Dose Naltrexone for Eczema: How It May Ease Stubborn Itch
/image%2F3334645%2F20260412%2Fob_d5c318_odig4-nhn.jpg)
Eczema, also known as atopic dermatitis, causes red, dry, and inflamed skin that often feels unbearably itchy. The itch can become so intense that people scratch until the skin breaks, leading to more inflammation, infections, and a frustrating cycle that is hard to break. Standard treatments such as moisturizers, steroid creams, and newer targeted medicines help many people, but some still struggle with constant itching that does not fully respond. In recent years, doctors have explored low-dose naltrexone as an additional option specifically for this kind of stubborn itch.
Naltrexone is a medicine that has been used for decades in much higher doses to help people overcome opioid addiction. At those higher doses it completely blocks opioid receptors in the brain and body. When the same medicine is given in very small amounts, usually between 1.5 and 4.5 milligrams per day, it behaves differently. This low-dose form, often called LDN, is taken orally once a day or sometimes prepared as a cream that is applied directly to the skin. Because the dose is so low, the medicine only briefly occupies the opioid receptors rather than locking them for hours. This temporary blockade triggers the body to respond in a helpful way.
The body reacts to the short-term blockade by producing more of its own natural pain-relieving and calming chemicals, known as endorphins. It also makes more opioid receptors on cells. These extra endorphins and receptors appear to quiet down overactive itch signals both in the skin and in the nerves that carry those signals to the brain. At the same time, low-dose naltrexone gently turns down certain inflammatory pathways. It blocks a receptor called TLR4 on immune cells, which reduces the release of chemicals that fuel swelling and irritation. In eczema, where the immune system is already overreacting and driving Th2-type inflammation, this mild dampening effect can help restore some balance without suppressing the entire immune system.
Opioid receptors are not only in the brain; they are also present throughout the layers of the skin. In people with chronic eczema, these skin receptors are often less active than normal. Low-dose naltrexone seems to bring them back online. Studies using skin biopsies have shown that after a short period of treatment, the number of these receptors in the outer layer of the skin increases. The result is faster and stronger relief from the urge to scratch. One small study using a 1 percent naltrexone cream on patients with severe eczema found that itch scores dropped by about 29 percent after just two weeks, and the cream worked noticeably faster than a plain cream.
Oral low-dose naltrexone has also been looked at for itch caused by eczema. A double-blind study that compared naltrexone to a placebo showed that the medicine reduced itching more effectively in people with atopic dermatitis. Researchers noted that the benefit came without major changes to the skin’s appearance in every case, but the relief from itch was meaningful enough to improve daily life and sleep. Because eczema is driven by both immune overactivity and nerve hypersensitivity, the combined anti-inflammatory and nerve-calming actions of low-dose naltrexone make it a logical choice for cases where the itch-scratch cycle feels impossible to stop.
Low-dose naltrexone is not a cure for eczema and does not replace proven treatments such as barrier creams or prescription anti-inflammatory medicines. Instead, it is used as an add-on therapy when itch remains a major problem. Some doctors prescribe the oral capsules, while others prefer a compounded cream that can be rubbed onto the worst patches. The medicine is generally well tolerated. At the low doses used, side effects are usually mild and may include temporary vivid dreams, mild nausea, or trouble sleeping during the first week or two. It is important for people to discuss low-dose naltrexone with their doctor before starting, because it is used off-label for skin conditions and may not be suitable for everyone, especially those already taking certain pain medicines or who have specific liver or kidney issues.
Research into low-dose naltrexone for eczema is still growing. Most of the available information comes from small studies, case reports, and reviews rather than large, long-term trials. Even so, the existing data suggest that this approach can offer real relief for the relentless itch that many people with eczema face. By gently adjusting the body’s own chemical signals and calming both inflammation and nerve sensitivity, low-dose naltrexone provides a different kind of help than traditional medicines. For those whose eczema itch has been difficult to control, it may be worth exploring with a knowledgeable healthcare provider.
How LDN Boosts Opioid Receptors in Eczema Skin
Low-dose naltrexone (LDN) causes a transient (short-term) blockade of opioid receptors in the skin (lasting only a few hours due to the low dose).
The body interprets this brief blockade as a signal that more receptors are needed, so it responds with a compensatory upregulation — increasing the number and sensitivity of opioid receptors (including mu, delta, and sometimes favoring kappa receptors) as well as natural endorphins.
In eczema studies, skin biopsies have shown this increase in epidermal opioid receptors after topical or oral LDN, which helps strengthen the skin’s natural “anti-itch brake.”
It is well-accepted and observed in dermatology literature and skin studies, but the exact cellular details are still considered partially understood (homeostatic rebound effect).
(Source : Grok)
